Types of MS (Photo credit: Wikipedia)
Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient’s own cells.
For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.
Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research. This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.
Stem cell lines and oligodendrocytes allow researchers to “turn back the clock” and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed. The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.
“We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases,” said Susan L. Solomon, NYSCF Chief Executive Officer.
Take me to the complete story . . .
The Latest on: Cell replacement therapy
via Google News
The Latest on: Cell replacement therapy
- U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapyon March 5, 2021 at 5:03 pm
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta® (axicabtagene ciloleucel) for the treatment of ...
- Cellectis SA (CLLS) Q4 2020 Earnings Call Transcripton March 5, 2021 at 12:30 pm
Q4 2020 Earnings CallMar 5, 2021, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings. Welcome to the Cellectis Fourth Quarter and Full ...
- TP63 basal cells are indispensable during endoderm differentiation into proximal airway cells on acellular lung scaffoldson March 4, 2021 at 4:00 pm
The use of decellularized whole-organ scaffolds for bioengineering of organs is a promising avenue to circumvent the shortage of donor organs for transplantation. However, recellularization of ...
- Regenerative Medicine Market Estimated to Record Highest CAGR by 2021-2025on March 3, 2021 at 8:58 pm
Regenerative Medicine Market AnalysisAccording to Verified Market Research, the Global Regenerative Medicine Market ...
- Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directionson March 2, 2021 at 4:00 pm
Adenovirus-associated defective virus particles. Science. 1965;149:754–6. Weitzman MD, Linden RM. Adeno-associated virus biology. In: Snyder RO, Moullier P (eds). Adeno-associated virus: methods and ...
- World-First Fabry Disease Treated With Gene Therapyon February 25, 2021 at 11:58 am
The modified stem cells were then transplanted back into each patient ... appear to react differently to those in other European countries. Enzyme Replacement Therapy Launched by Takeda in India In an ...
- A Canadian success story: World-first to treat Fabry disease with gene therapyon February 25, 2021 at 9:09 am
Results of a world-first Canadian pilot study on patients treated with gene therapy for Fabry disease show that the treatment is working and safe.
- Canadian pilot study uses gene therapy to successfully treat patients with Fabry diseaseon February 25, 2021 at 8:58 am
Results of a world-first Canadian pilot study on patients treated with gene therapy for Fabry disease show that the treatment is working and safe.
- A new combination therapy for treating rare, fatal Sanfilippo syndrome in childrenon February 24, 2021 at 3:27 pm
A study aiming to develop a new therapeutic technique could bring a revolution in our approach to treating rare, fatal Sanfilippo syndrome, a disorder that affects children as young as 2 years old and ...
- A combination therapy for treating severe neurological childhood disorderson February 24, 2021 at 1:20 pm
A study aiming to develop a new therapeutic technique could bring a revolution in our approach to treating rare, fatal Sanfilippo syndrome, a disorder that affects children as young as 2 years old and ...
via Bing News
